PD-1-IN-17 free base is a small molecule composed of heteroaromatic and aliphatic units designed to support interaction studies with biomolecular targets. Researchers use it to evaluate ligand-binding geometry, conformational states, and solvation effects. Its structural diversity facilitates mechanistic modeling. The free-base form assists in versatile analytical handling.
CAT No: R2274
CAS No:1673560-66-1
Synonyms/Alias:1673560-66-1;PD-1-IN-17;PD1-IN-1;PD-1-IN-17 free base;(2S)-2-[[(1S)-4-amino-1-[5-[(1S,2R)-1-amino-2-hydroxypropyl]-1,3,4-oxadiazol-2-yl]-4-oxobutyl]carbamoylamino]-3-hydroxypropanoic acid;(S)-2-(3-((S)-4-Amino-1-(5-((1S,2R)-1-amino-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl)-4-oxobutyl)ureido)-3-hydroxypropanoic acid;CHEMBL4458504;SCHEMBL19450456;EX-A4358;PD-1-IN-17?;AKOS040733979;AC-37062;DA-56651;MS-26046;HY-101097;CS-0020822;G16430;
PD-1-IN-17 free base is a small-molecule biochemical compound recognized for its potent and selective inhibitory activity against the programmed cell death protein 1 (PD-1) pathway. As a synthetic PD-1 inhibitor, it plays a significant role in modulating immune checkpoint signaling, making it a valuable tool in immunological and molecular biology research. The compound's mechanism of action involves direct interference with PD-1, a key regulatory receptor expressed on activated T cells, which is central to the maintenance of immune tolerance and the prevention of autoimmunity. Researchers utilize PD-1-IN-17 free base to dissect cellular signaling cascades, investigate immune cell interactions, and explore the molecular underpinnings of immune regulation in both normal and pathological contexts.
Immune checkpoint research: PD-1-IN-17 free base is widely employed in studies aiming to elucidate the regulatory mechanisms of immune checkpoints. By inhibiting PD-1, the compound enables researchers to probe the functional consequences of checkpoint blockade on T cell activation, proliferation, and cytokine production. This is particularly relevant for understanding the molecular basis of immune evasion in various biological systems, as well as for identifying novel modulators of immune responses in vitro and ex vivo.
Signal transduction analysis: The compound serves as a precise tool for dissecting intracellular signaling pathways downstream of PD-1 engagement. By blocking PD-1-mediated inhibitory signals, investigators can delineate the effects on key signaling molecules such as SHP-2, PI3K, and Akt. This facilitates the mapping of signal transduction events that govern T cell fate decisions, providing valuable insights into the dynamic regulation of immune cell function under different experimental conditions.
Drug discovery and screening: In the context of early-stage drug discovery, PD-1-IN-17 free base is utilized as a reference inhibitor in high-throughput screening assays and structure-activity relationship (SAR) studies. Its well-characterized inhibitory profile makes it suitable for benchmarking the activity of novel small-molecule candidates targeting the PD-1/PD-L1 interaction. This application supports the identification and optimization of next-generation immune modulators with improved potency and selectivity.
Cellular assay development: The compound is frequently incorporated into cell-based assay systems designed to model immune checkpoint dynamics. By providing a robust means to modulate PD-1 signaling, it enables the development and validation of functional assays that measure T cell responses, cytokine secretion, and cytotoxic activity. Such assays are essential for evaluating the immunomodulatory potential of new compounds and for advancing the understanding of cell-mediated immunity in controlled laboratory settings.
Mechanistic immunology research: PD-1-IN-17 free base is instrumental in mechanistic studies aimed at unraveling the complex interplay between immune checkpoints and other regulatory pathways. Researchers leverage its selective inhibition to investigate cross-talk between PD-1 and co-stimulatory or co-inhibitory receptors, as well as to assess the impact of checkpoint modulation on immune cell differentiation and memory formation. These investigations contribute to a deeper comprehension of immune homeostasis and the factors that influence immune tolerance and activation.
Collectively, the diverse applications of PD-1-IN-17 free base underscore its significance as a research tool in immunology, molecular biology, and drug discovery. Its ability to selectively modulate PD-1 signaling provides a versatile platform for advancing knowledge of immune regulation, supporting assay development, and informing the design of novel immunomodulatory strategies in preclinical research environments.
1. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
2. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
5. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More